Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) EBT Margin (2023 - 2025)

Entrada Therapeutics has reported EBT Margin over the past 3 years, most recently at 3007.85% for Q4 2025.

  • Quarterly results put EBT Margin at 3007.85% for Q4 2025, down 300592.0% from a year ago — trailing twelve months through Dec 2025 was 561.84% (down 59339.0% YoY), and the annual figure for FY2025 was 561.84%, down 59339.0%.
  • EBT Margin for Q4 2025 was 3007.85% at Entrada Therapeutics, down from 2693.93% in the prior quarter.
  • Over the last five years, EBT Margin for TRDA hit a ceiling of 61.03% in Q2 2024 and a floor of 3007.85% in Q4 2025.
  • Median EBT Margin over the past 3 years was 39.43% (2023), compared with a mean of 665.19%.
  • Biggest five-year swings in EBT Margin: soared 12752bps in 2024 and later crashed -300592bps in 2025.
  • Entrada Therapeutics' EBT Margin stood at 21.98% in 2023, then crashed by -109bps to 1.94% in 2024, then tumbled by -155270bps to 3007.85% in 2025.
  • The last three reported values for EBT Margin were 3007.85% (Q4 2025), 2693.93% (Q3 2025), and 2201.28% (Q2 2025) per Business Quant data.